Skip to main content
PMC home page
Clinical Cardiology logoLink to Clinical Cardiology
. 2009 Feb 3;23(1):18–23. doi: 10.1002/clc.4960230105

Anomalies in the dosing of diltiazem

Peter E Pool 1,✉
PMCID: PMC6654899  PMID: 10680025

Abstract

From early research, investigators understood that the dose of diltiazem required for the treatment of hypertension (commonly 360 mg/day) was greater than that required for the treatment of angina (commonly 240 mg/day). Nonetheless, studies of recent prescribing practices show that the 240 and 180 mg capsule strengths constitute more than 70% of the diltiazem prescriptions for hypertension. Physicians became accustomed to the lower antianginal doses of diltiazem for 7 years before a hypertension indication was approved. Subsequently, these dosing levels were reinforced by the production of once‐a‐day formulations with highest capsule strengths of 240 mg and 300 mg. These strengths were dictated by the sheer bulk of the formulations, which limited how much diltiazem could be inserted into the #00 capsule, the largest capsule that can be comfortably administered. An examination of the combined data from the six randomized, blinded, and placebo‐controlled trials submitted to the FDA for the original new drug applications of the three formulations of diltiazem available in the United States shows a clear linear dose‐response relationship between diltiazem dose and blood pressure lowering through the 480‐‐540 mg/day range. It also demonstrates that the 90‐‐120 mg/day range is the “no‐effect dose.” These conclusions are supported by a MEDLINE review of all other studies of multilevel dosing of higher dose levels of diltiazem. The data support the conclusion that diltiazem is generally underdosed, but when properly dosed may be the single most potent antihypertensive overall.

Keywords: diltiazem, dosing, calcium antagonist, hypertension, coronary artery disease.

Full Text

The Full Text of this article is available as a PDF (639.9 KB).

Reference

  • 1. Pool PE: Diltiazem In Cardiovascular Drug Therapy, 2nd ed., (Ed. Messerli FH.), p. 931–971. Philadelphia: W. B. Saunders, 1996. [Google Scholar]
  • 2. Bala Subramanian V, Khurmi NS, Bowles MJ, O'Hara M, Raftery EB: Objective evaluation of three dose levels of diltiazem in patients with chronic stable angina. J Am Coll Cardiol 1983; 1: 1144–1153 [DOI] [PubMed] [Google Scholar]
  • 3. Low RI, Takeda P, Lee G, Mason DT, Awan NA, DeMaria AN: Effects of diltiazem‐induced calcium blockade upon exercise capacity in effort angina due to chronic coronary artery disease. Am Heart J 1981; 101: 713–718 [DOI] [PubMed] [Google Scholar]
  • 4. Starling MR, Crawford MH, O'Rourke RA: Diltiazem: Effects on exercise performance in patients with coronary artery disease. Int J Cardiol 1982; 1: 229–237 [DOI] [PubMed] [Google Scholar]
  • 5. Hossack KF, Pool PE, Steele P, Crawford MH, DeMaria AN, Cohen LS, Ports TA: Efficacy of diltiazem in angina on effort: A multicenter trial. Am J Cardiol 1982; 49: 567–572 [DOI] [PubMed] [Google Scholar]
  • 6. Lindenberg BS, Weiner DA, McCabe CH, Cutler SS, Ryan TJ, Klein MD: Efficacy and safety of incremental doses of diltiazem for the treatment of stable angina pectoris. J Am Coll Cardiol 1983; 2: 1129–1133 [DOI] [PubMed] [Google Scholar]
  • 7. Petru MA, Crawford MH, Sorensen SG, Chaudhuri TK, Levine S, O'Rourke RA: Short‐ and long‐term efficacy of high‐dose oral diltiazem for angina due to coronary artery disease: A placebo‐controlled, randomized, double‐blind crossover study. Circulation 1983; 68: 139–147 [DOI] [PubMed] [Google Scholar]
  • 8. Burris JF, Weir MR, Oparil S, Weber M, Cady WJ, Stewart WH: An assessment of diltiazem and hydrochlorothiazide in hypertension. Application of factorial trial design to a multicenter clinical trial of combination therapy. J Am Med Assoc 1990; 263: 1507–1512 [PubMed] [Google Scholar]
  • 9. Hedner T, Thulin T, Gustafsson S, Olsson SO: A comparison of diltiazem and metoprolol in hypertension. Eur J Clin Pharmacol 1990; 39: 427–433 [DOI] [PubMed] [Google Scholar]
  • 10. Pool PE, Massie BM, Venkataraman K, Hirsch AT, Samant DR, Seagren SC, Gaw J, Salel AF, Tubau JF: Diltiazem as monotherapy for systemic hypertension: A multicenter, randomized, placebo‐controlled trial. Am J Cardiol 1986; 57: 212–217 [DOI] [PubMed] [Google Scholar]
  • 11. Pool PE, Nappi JM, Weber MA: Antihypertensive monotherapy with tablet (prompt‐release) diltiazem: Multicenter controlled trials. Cardiovasc Drugs Ther 1990; 4: 1089–1096 [DOI] [PubMed] [Google Scholar]
  • 12. Massie BM, Der E, Herman TS, Topolski P, Park GD, Stewart WH: 24‐Hour efficacy of once‐daily diltiazem in essential hypertension. Clin Cardiol 1992; 15: 365–368 [DOI] [PubMed] [Google Scholar]
  • 13. Felicetta JV, Serfer HM, Cutler NR, Comstock TJ, Huber GL, Weir MR, Hafner K, Park GD: A dose‐response trial of once‐daily diltiazem. Am Heart J 1992; 123: 1022–1026 [DOI] [PubMed] [Google Scholar]
  • 14. Whelton A, Eff J, Magner DJ: Sustained antihypertensive activity of diltiazem SR: Double‐blind, placebo‐controlled study with 24‐hour ambulatory blood pressure monitoring. J Clin Pharmacol 1992; 32: 808–815 [DOI] [PubMed] [Google Scholar]
  • 15. Woehler TR, Eff J, Graney W, Head D, Ziemniak J, Magner D: Multicenter evaluation of the efficacy and safety of sustained‐release diltiazem hydrochloride for the treatment of hypertension. Clin Ther 1992; 14: 148–157 [PubMed] [Google Scholar]
  • 16. Weir MR, Weber MA, Punzi HA, Serfer HM, Rosenblatt S, Cady WJ: A dose escalation trial comparing the combination of diltiazem SR and hydrochlorothiazide with the monotherapies in patients with essential hypertension. J Hum Hypertens 1992; 6: 133–138 [PubMed] [Google Scholar]
  • 17. Graney WF: Clinical experience with a once‐daily, extended‐release formulation of diltiazem in the treatment of hypertension. Am J Med 1992; 93: 56S–64S [DOI] [PubMed] [Google Scholar]
  • 18. Weiner DA, Cutler SS, Klein MD: Efficacy and safety of sustained‐release diltiazem in stable angina pectoris. Am J Cardiol 1986; 57: 6–9 [DOI] [PubMed] [Google Scholar]
  • 19. Khurmi NS, Bowles MJ, O'Hara MJ, Bala Subramanian V, Raftery EB: Long‐term efficacy of diltiazem assessed with multistage graded exercise tests in patients with chronic stable angina pectoris. Am J Cardiol 1984; 54: 738–743 [DOI] [PubMed] [Google Scholar]
  • 20. Go M, Hollenberg M: Improved efficacy of high‐dose versus medium‐ and low‐dose diltiazem therapy for chronic stable angina pectoris. Am J Cardiol 1984; 53: 669–673 [DOI] [PubMed] [Google Scholar]
  • 21. Humen DP, O'Brien P, Purves P, Johnson D, Kostuk WJ: Effort angina with adequate beta‐receptor blockade: Comparison with diltiazem alone and in combination. J Am Coll Cardiol 1986; 7: 329–335 [DOI] [PubMed] [Google Scholar]
  • 22. Thadani U, Glasser S, Bittar N, Beach CL: Dose‐response evaluation of once‐daily therapy with a new formulation of diltiazem for stable angina pectoris. Am J Cardiol 1994; 74: 9–17 [DOI] [PubMed] [Google Scholar]
  • 23. Materson BJ, Reda DJ, Cushman WC, Massie BM, Freis ED, Kochar MS, Hamburger RJ, Fye C, Lakshman R, Gottdiener J, Ramirez EA, Henderson WG: Single‐drug therapy for hypertension in men: A comparison of six antihypertensive agents with placebo (correction: N Engl J Med 1994;3301689). N Engl J Med 1993; 328: 914–921 [DOI] [PubMed] [Google Scholar]
  • 24. IMS National Disease and Therapeutic Index (Drug) 1998; 3: 2522–2526 [Google Scholar]
  • 25. Cohen JS, Insel PA: The Physicians' Desk Reference. Problems and possible improvements. Science 1995; 269: 164–169 [PubMed] [Google Scholar]
  • 26. Physicians' Desk Reference (53rd ed.). Montvale, N.J.: Medical Economics Data, 1999. [Google Scholar]
  • 27. Neutel JM, Smith DH, Frishman WH: Optimization of antihypertensive therapy with a novel, extended‐release formulation of diltiazem: Results of a practice‐based clinical study. Clin Ther 1997; 19: 1379–1393 [DOI] [PubMed] [Google Scholar]
  • 28. Lippert CL, Arumugham T, Bhargava VO, Eller M, Weir SJ: The relative bioavailability of two marketed controlled release diltiazem dosage forms at steady state in healthy volunteers. Biopharm Drug Dispos 1996; 17: 43–53 [DOI] [PubMed] [Google Scholar]
  • 29. Eradiri O, Midha KK: Comparison of diltiazem bioavailability from 3 marketed extended‐ release products for once‐daily administration: Implications of chronopharmacokinetics and dynamics. Int J Clin Pharmacol Ther 1997; 35: 369–373 [PubMed] [Google Scholar]
  • 30. Dimmitt DC, Bhargava VO, Arumugham T, Eller M, Weir SJ: Relative bioavailability of Cardizem CD and Tiazac controlled‐release diltiazem dosage forms after single and multiple dosing in healthy volunteers. Am J Ther 1998; 5: 173–179 [DOI] [PubMed] [Google Scholar]
  • 31. Lacourciere Y, Poirier L, Lefebvre J, Burford RG: Clinical efficacy of force titrated doses of diltiazem extended‐release. A placebo controlled study. Am J Hypertens 1995; 8: 282–286 [DOI] [PubMed] [Google Scholar]
  • 32. Food and Drug Administration Freedom of Information Staff. File F92–00454, NDA 20–026. 1992; 2243
  • 33. Rich S, Kaufmann E, Levy PS: The effect of high doses of calcium‐channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327: 76–81 [DOI] [PubMed] [Google Scholar]
  • 34. Menard J, Chatellier G, Degoulet P, Plouin P‐F, Corvol P: How much can blood pressure be lowered? Hypertension 1983; 5 (suppl III): III‐21–III‐25 [DOI] [PubMed] [Google Scholar]
  • 35. Djian J, Ferme I, Zannad F, Chaignon M, Asmar R: Effects of sustained‐release diltiazem on blood pressure and serum lipids: A multicenter, randomized, placebo‐controlled study. J Cardiovasc Pharmacol 1990; 16 (suppl 1): S38–S45 [PubMed] [Google Scholar]
  • 36. Fiddes R, Heym H, Hilty W, Lewin AJ, Codispoti J, McNally C, Stokes A, Gilderman L: Blood pressure control with diltiazem XR, a novel extended‐release formulation of diltiazem HCl, in mature and elderly hypertensive patients. Clin Ther 1994; 16: 209–221 [PubMed] [Google Scholar]
  • 37. Materson BJ, Reda DJ, Preston RA, Cushman WC, Massie BM, Freis ED, Kochar MS, Hamburger RJ, Fye C, Lakshman R, Gottdeiner J, Ramirez EA, Henderson WG: Response to a second single antihypertensive agent used as monotherapy for hypertension after failure of the initial drug. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Arch Intern Med 1995; 155: 1757–1762 [PubMed] [Google Scholar]
  • 38. Ollivier JP, Wajman A, Stalla Bourdillon A: Antihypertensive efficacy of optimally titrated doses of once‐daily sustained‐release diltiazem: A placebo‐controlled trial. DILPLACOMP Study Group. Cardiology 1995; 86: 481–487 [DOI] [PubMed] [Google Scholar]
  • 39. Nilsson P, Lindholm LH, Hedner T: The Diltiazem Different Doses Study—A dose‐response study of once‐daily diltiazem therapy for hypertension. J Cardiovasc Pharmacol 1996; 27: 469–475 [DOI] [PubMed] [Google Scholar]
  • 40. Cutler NR, Eff J, Fromell G, Brass EP, Archer S, Chrysant SG, Fiddes R: Dose‐ranging study of a new, once‐daily diltiazem formulation for patients with stable angina. J Clin Pharmacol 1995; 35: 189–195 [DOI] [PubMed] [Google Scholar]
  • 41. Logan RL: The efficacy and tolerance to three doses of diltiazem in elderly patients with stable angina. Eur J Clin Pharmacol 1988; 33: 561–564 [DOI] [PubMed] [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES